— Research note —
Semaglutide
Long-acting GLP-1 receptor agonist with extensive clinical research in glycemic control, body-weight regulation, and cardiovascular endpoints.
Semaglutide is a 31-amino-acid analog of human glucagon-like peptide-1 (GLP-1) developed by Novo Nordisk. The molecule incorporates two substitutions at positions 8 and 34 (Aib and Arg, respectively) and a C18 fatty diacid attached via a gamma-glutamic acid and double oxyethylene linker at lysine 26. These modifications confer resistance to dipeptidyl peptidase-4 cleavage and promote reversible albumin binding, extending the plasma half-life to approximately one week.
The compound has been the subject of one of the largest peptide clinical research programs ever conducted. The SUSTAIN series investigated glycemic outcomes in type 2 diabetes, the STEP series examined weight regulation, and the SELECT trial evaluated cardiovascular event reduction in non-diabetic individuals with established atherosclerotic disease. Across these programs, researchers have consistently reported dose-dependent reductions in HbA1c, body weight, and major adverse cardiovascular events.
Beyond metabolic endpoints, semaglutide has become a tool molecule in academic research probing the central nervous system actions of GLP-1 signaling. Investigators have used the compound in studies of food reward, addictive behavior in rodent self-administration models, neuroinflammation in Alzheimer's disease pre-clinical models, and renal protection in chronic kidney disease cohorts (FLOW trial). Its tractable pharmacokinetics and well-characterized receptor selectivity make it a frequent reference compound in incretin pharmacology.
Semaglutide is supplied here as a research chemical for in vitro and ex vivo investigation and is not intended for human use. Its inclusion in the BHC catalog reflects its central role in modern peptide research rather than any endorsement of off-label application.
Mechanism
Semaglutide is a selective agonist at the GLP-1 receptor, a class B G-protein coupled receptor. Receptor engagement activates Gas, elevates intracellular cAMP, and recruits beta-arrestin-1 with kinetics modified by the fatty acid modification. In pancreatic beta cells, this signaling potentiates glucose-stimulated insulin secretion, a glucose-dependent action that limits the risk of hypoglycemia in research models.
Within the hypothalamic arcuate nucleus, GLP-1 receptor activation depolarizes POMC neurons and inhibits AgRP neurons, an effect demonstrated by electrophysiological recordings in murine slice preparations. Engagement of receptors in the area postrema and nucleus tractus solitarius contributes to observed reductions in food intake and delayed gastric emptying. In rodent reward circuits, semaglutide has been shown to modulate dopamine release in the nucleus accumbens, providing a mechanistic basis for ongoing research into addictive behaviors.
Research history
Semaglutide originated from Novo Nordisk's program to extend the duration of action of liraglutide, a once-daily GLP-1 analog. Disclosure of the molecule appeared in 2015 with publication of the phase 2 dose-ranging trial. The SUSTAIN program (SUSTAIN-1 through SUSTAIN-10) established the once-weekly formulation across type 2 diabetes populations, with SUSTAIN-6 (2016) demonstrating cardiovascular event reduction.
The STEP obesity program, beginning with STEP 1 in 2021, reported mean weight loss approaching 15 percent over 68 weeks at the 2.4 mg dose. The PIONEER trials established an oral formulation co-formulated with the absorption enhancer SNAC, a milestone for peptide drug delivery research. The SELECT cardiovascular outcomes trial (2023) demonstrated a 20 percent reduction in major adverse cardiovascular events in overweight individuals without diabetes.
Subsequent research has expanded into chronic kidney disease (FLOW, 2024), metabolic dysfunction-associated steatohepatitis (ESSENCE, 2024-2025), Alzheimer's disease (evoke and evoke+, ongoing), and substance use disorders. The molecule has become a probe of choice for academic investigations of incretin biology and a benchmark against which newer multi-agonist peptides are compared.
References
- Marso SP, et al. 2016. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. PMID: 27633186
- Wilding JPH, et al. 2021. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. PMID: 33567185
- Lincoff AM, et al. 2023. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. PMID: 37952131
- Perkovic V, et al. 2024. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. PMID: 38785503
- Lau J, et al. 2015. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. PMID: 26308095
- Knudsen LB, Lau J. 2019. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol. PMID: 31031702
Do you have any questions about Semaglutide?
Pick a path. The research assistant has the full literature context loaded.
Information presented in third-person scientific context. Research use only. Not medical advice; not for human consumption.